BioVaxys Technology Corp. (CSE: BIOV) announced positive results from a phase 1 clinical study of its experimental treatment maveropepimut-S combined ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE